The International Journal of Hypertension, published by HINDAWI LTD, is a pivotal open-access journal dedicated to advancing knowledge in the field of hypertension and cardiovascular health. Since its inception in 2010, the journal has provided a vital platform for researchers, clinicians, and students to disseminate innovative findings and comprehensive reviews spanning various aspects of hypertension management, pathophysiology, and epidemiology. Residing in Q3 of the Internal Medicine category and ranked 75 out of 167 in the Scopus rankings, it reflects a commitment to quality and relevance in medical research. With a global reach, the journal aims to foster collaboration and knowledge exchange, contributing significantly to the scientific community's efforts to combat hypertension-related health issues. Accessible since 2010, this journal exemplifies the principles of open science, ensuring that critical research is available to all stakeholders in the field.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.

FREE RADICAL BIOLOGY AND MEDICINE, published by Elsevier Science Inc, is a premier journal dedicated to the field of biochemistry and medical physiology. With an ISSN of 0891-5849 and an E-ISSN of 1873-4596, this journal stands out with its impressive ranking in the 2023 category quartiles: Q1 in Biochemistry and Q1 in Physiology (medical). Specifically, it has achieved a remarkable position of 29th out of 438 in Biochemistry and 8th out of 113 in Physiology, placing it firmly in the 93rd percentile of its field, as per Scopus rankings. Since its inception in 1987, the journal has focused on advancing the understanding of free radicals and their role in biological processes, encompassing a wide range of topics from oxidative stress to therapeutic applications. Although it does not currently offer open access, the journal's rigorous peer-review process and impactful research ensure that it remains a valuable resource for researchers and professionals seeking to explore the intricate relationships between free radicals and health. The journal's headquarters are located at STE 800, 230 Park Ave, New York, NY 10169, reflecting its esteemed place within the scientific community and commitment to high-quality research.

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

CLINICAL SCIENCE, published by PORTLAND PRESS LTD, is a prestigious journal with an established history that dates back to 1946. Renowned for its rigorous peer-reviewed articles, the journal is dedicated to advancing knowledge in the field of medicine, particularly in the nuances of clinical science and translational research. With an impressive Q1 ranking in the **Medicine (miscellaneous)** category and a Scopus rank of #32 out of 636 in general medicine, it is firmly positioned in the top 5% percentile of its field, making it an essential resource for researchers, practitioners, and students aiming to stay at the forefront of the discipline. Although the journal operates on a traditional subscription model, its influence and accessibility ensure that critical findings and innovative methodologies reach a wide audience, fostering collaboration and progress within the global medical community. The journal seeks to publish groundbreaking studies, critical reviews, and insights that can translate into improved clinical practices, thus reinforcing its mission to enhance patient care and medical knowledge.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, published by Elsevier Science Ltd, is a prestigious academic journal dedicated to advancing the knowledge and understanding of the intricate relationships between nutrition, metabolism, and cardiovascular health. With an impressive HIndex and a consistent trajectory of high-impact research, this journal occupies a commendable position in the academic landscape, achieving Q1 rankings in both Cardiology and Cardiovascular Medicine, as well as in Nutrition and Dietetics for the year 2023. The journal’s Scopus rankings further solidify its reputation, occupying top percentiles across various categories, making it an essential resource for researchers, healthcare professionals, and students keen on exploring the latest findings in the field. Although it is not an open access journal, readers can access a wealth of knowledge that spans from 1996 to 2024, with articles that cover diverse topics in endocrinology, diabetes, and metabolism. By disseminating groundbreaking research and reviews, NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES aims to foster innovation and evidence-based practices that contribute to improved health outcomes worldwide.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.